ChemDiv and SK Corporation Extend Collaboration into 2008
News Feb 15, 2006
Under this agreement, ChemDiv is supplying SK Corporation with discovery chemistry libraries and medicinal chemistry services in addition to assisting the company in hit-to-lead optimization projects initiated at SK Institute of Technology in Daejeon.
"We are very proud that SK Corporation, Korea's leading integrated energy and chemical company and a pioneer in new drug development business, maintains ChemDiv as the partner for their new drug discovery research projects," said Nikolay Savchuk, President of ChemDiv.
"This collaboration is an indicator of continued confidence in the value ChemDiv brings as a partner to the SK Corporation Drug Discovery Program."
"We look forward to our continued collaboration with ChemDiv," said Dr. Byongsung Kwak, Head of BioPharmaceutical Division of SK Corporation.
"We are confident that the company's diverse sets of drug-like small molecules and their state-of-the-art facilities and capabilities in both the US and Europe will continue to be a significant asset to SK Corporation in our research, development, manufacturing and marketing of drugs, active substances and intermediates."
Bicycle Therapeutics Expands Strategic Partnership with AstraZenecaNews
New programs added in respiratory and cardio-metabolic diseases.READ MORE
Worldwide Clinical Trials Receives 2018 CRO Leadership AwardsNews
Life Science Leader and Industry Standard Research assess 70 contract research organizations, honoring Worldwide Clinical Trials for fifth consecutive year.READ MORE
WuXi Biologics to Invest in Biologics Manufacturing Facility in SingaporeNews
WuXi Biologics' first overseas site in Asia.READ MORE
Comments | 0 ADD COMMENT
2nd Annual Artificial Intelligence in Drug Development Congress
Sep 20 - Sep 21, 2018